Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
企業コードMGX
会社名Metagenomi Inc
上場日Feb 09, 2024
最高経営責任者「CEO」Dr. Brian C. Thomas, Ph.D.
従業員数202
証券種類Ordinary Share
決算期末Feb 09
本社所在地5959 Horton St
都市EMERYVILLE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94608
電話番号15108714880
ウェブサイトhttps://metagenomi.co/
企業コードMGX
上場日Feb 09, 2024
最高経営責任者「CEO」Dr. Brian C. Thomas, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし